AI Article Synopsis

  • Gamma oscillations reflect key brain processes related to perception and cognition, involving specific types of interneurons and are notably altered in disorders like schizophrenia and autism.
  • The auditory steady-state response (ASSR) serves as a key measure of these gamma oscillations, showing reduction in patients with neuropsychiatric conditions, though the underlying neural mechanisms remain unclear.
  • A study using high-density electrocorticography in epilepsy patients revealed that ASSR exhibits a complex, frequency-tuned distribution across various cortical regions, indicating differentiated processing pathways for auditory information.

Article Abstract

Gamma oscillations are physiological phenomena that reflect perception and cognition, and involve parvalbumin-positive γ-aminobutyric acid-ergic interneuron function. The auditory steady-state response (ASSR) is the most robust index for gamma oscillations, and it is impaired in patients with neuropsychiatric disorders such as schizophrenia and autism. Although ASSR reduction is known to vary in terms of frequency and time, the neural mechanisms are poorly understood. We obtained high-density electrocorticography recordings from a wide area of the cortex in 8 patients with refractory epilepsy. In an ASSR paradigm, click sounds were presented at frequencies of 20, 30, 40, 60, 80, 120, and 160 Hz. We performed time-frequency analyses and analyzed intertrial coherence, event-related spectral perturbation, and high-gamma oscillations. We demonstrate that the ASSR is globally distributed among the temporal, parietal, and frontal cortices. The ASSR was composed of time-dependent neural subcircuits differing in frequency tuning. Importantly, the frequency tuning characteristics of the late-latency ASSR varied between the temporal/frontal and parietal cortex, suggestive of differentiation along parallel auditory pathways. This large-scale survey of the cortical ASSR could serve as a foundation for future studies of the ASSR in patients with neuropsychiatric disorders.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408476PMC
http://dx.doi.org/10.1093/cercor/bhab103DOI Listing

Publication Analysis

Top Keywords

gamma oscillations
8
assr
8
patients neuropsychiatric
8
neuropsychiatric disorders
8
frequency tuning
8
global parallel
4
parallel cortical
4
cortical processing
4
processing based
4
based auditory
4

Similar Publications

Motor cortical high-gamma oscillations (60-90 Hz) occur at movement onset and are spatially focused over the contralateral primary motor cortex. Although high-gamma oscillations are widely recognized for their significance in human motor control, their precise function on a cortical level remains elusive. Importantly, their relevance in human stroke pathophysiology is unknown.

View Article and Find Full Text PDF

MEG Biomarkers in relation to plasma neuropathology biomarkers of Alzheimer’s disease.

Alzheimers Dement

December 2024

Universidad Complutense de Madrid, Madrid, Madrid, Spain

Background: The preclinical stage of Alzheimer’s disease (AD) has gained attention for the window of opportunity it opens for early detection and intervention. Given the high invasiveness of PET and CSF markers, electrophysiology and plasma biomarkers are being studied as alternate biomarkers for early detection and disease tracking. The aim of this study is twofold.

View Article and Find Full Text PDF

Background: Preclinical investigations in Alzheimer’s disease (AD) have highlighted the efficacy of gamma sensory stimulation in mitigating AD‐related pathologies. Cognito Therapeutics, Inc. (Cambridge, MA) has designed the Sensory Stimulation System for safe at‐home usage, to induce EEG‐confirmed gamma oscillations as a potential treatment for AD.

View Article and Find Full Text PDF

Background: In the EEG research of Alzheimer's Disease (AD) and other diseases belonging to dementia, the literature is rapidly growing to indicate biomarkers specific to the type of dementia. The literature showed firm conclusions that decreasing event‐related delta and theta responses could be a biomarker showing cognitive decline (Güntekin et al. 2022).

View Article and Find Full Text PDF

Background: The OVERTURE (NCT03556280) randomized controlled trial (RCT) evaluated evoked gamma oscillation therapy using Cognito’s medical device (CogTx‐001) in mild‐moderate Alzheimer’s disease (AD). Brain atrophy, as measured by whole brain volume (WBV), is a key indicator of neurodegeneration in AD and may be influenced by baseline covariates such as age, disease stage, APOE4 carrier status, and PET amyloid levels, as well as treatment. We analyzed OVERTURE MRI whole brain volume outcomes across these key baseline subgroups.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!